Compare TransMedics Group Inc (TMDX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tesla, Inc. — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 540.1× TransMedics Group Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Tesla, Inc. for 88 Days on average.
| TMDX | TSLA | |
|---|---|---|
Market Cap | $2.74B | $1.48T |
Volume | 949,331 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $489.88 |
52-Week Low | $61.99 | $298.16 |
Typical Hold Time | 24 Days | 88 Days |
Enterprise Value | $3.13B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Tesla (TSLA) trades at $375.03, down 0.68% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue at $94.83B in 2025 and a net income margin of 4%. Analyst consensus is a Buy with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and high valuation multiples. The stock offers growth potential from AI and robotics expansion, but faces headwinds from competitive pressures and margin compression. Investors should weigh long-term disruptive potential against current profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
